Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | NPC1 | O15118 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.45 |
| ▸ | CHKA | P35790 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | RXRA | P19793 | 1/20 | 0.43 |
| ▸ | RXRB | P28702 | 1/20 | 0.43 |
| ▸ | RXRG | P48443 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5581612 | 0.88 | TSHR (0.60) | NAPRTKMT2AMEN1NPC1POLB | |
| SCHEMBL12893701 | 0.83 | CHRM5 (0.43) | NAPRTKMT2AKDM4ECHRM5CHKA | |
| SCHEMBL1221272 | 0.82 | TSHR (0.54) | NAPRTKMT2AMEN1NPC1POLB | |
| SCHEMBL4755619 | 0.82 | TSHR (0.54) | NAPRTKMT2AMEN1NPC1POLB | |
| SCHEMBL2636665 | 0.81 | MKNK1 (0.54) | KMT2AMEN1NPC1POLBKDM4E | |
| SCHEMBL12893704 | 0.80 | NOTUM (0.51) | KMT2AMEN1NPC1KDM4ETSHR | |
| SCHEMBL3409151 | 0.78 | CHRM5 (0.68) | KMT2AMEN1NPC1KDM4ETSHR | |
| SCHEMBL10811978 | 0.76 | HSP90AA1 (0.49) | KMT2AMEN1KDM4EHPGDALDH1A1 | |
| Isonicotinic Acid SCHEMBL1108 | 0.76 | — | — | |
| Isonicotinic Acid SCHEMBL1414914 | 0.76 | NAPRT (1.00) | NAPRTKMT2AMEN1KDM4ETP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2011140599-A1 | CHEMICAL COMPOUND ARRAYS USEFUL FOR DETECTING BACTERIAL PEPTIDES | MONASH UNIVERSITY (AU) | 2011-11-17 | — | — | WO | claimed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| US-20230127046-A1 | G9a INHIBITOR | RIKEN (JP) | 2023-04-27 | — | — | US | disclosed |
| WO-2011140599-A1 | CHEMICAL COMPOUND ARRAYS USEFUL FOR DETECTING BACTERIAL PEPTIDES | MONASH UNIVERSITY (AU) | 2011-11-17 | — | — | WO | disclosed |
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| US-7879880-B2 | such as [4-[(2-aminopyridin-4-yl)methyl]piperazin-1-yl]-[4-(pyridin-4-ylamino)phenyl]methanone, used for the treatment of inflammatory diseases, allergic conditions, diabetes, obesity, metabolic syndrome, cognition disorder, cardiovascular and nervous system disorders | SCHERING CORPORATION (US) | 2011-02-01 | — | — | US | disclosed |
| WO-2007075688-A2 | SUBSTITUTED ANILINE DERIVATIVES USEFUL AS HISTAMINE H3 ANTAGONISTS | SCHERING CORPORATION (US) | 2007-07-05 | — | — | WO | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | SCHERING CORPORATION | 2007-06-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070142394-A1 | Substituted aniline derivatives useful as histamine H3 antagonists | HRH3, CHRM2, HCRTR2 | NAPRT 3026/4885KMT2A 296/4885MEN1 536/4885 |
| US-20230127046-A1 | G9a INHIBITOR | EZH2, BMI1, DOT1L | NAPRT 4580/4885KMT2A 4/4885MEN1 1264/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.